To investigate the ability of urinary NGAL (uNGAL) in: (1) the differential diagnosis of AKI, (2) predicting the response to treatment with terlipressin and albumin in patients with Hepatorenal Syndrome (HRS)-AKI and (3) predicting in-hospital and 90-day mortality
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Terlipressin (Primary)
- Indications Hepatorenal syndrome
- Focus Therapeutic Use
- 23 Aug 2022 New trial record
- 26 Jun 2022 Results presented at The International Liver Congress 2022